FR14C0041I1 - - Google Patents
Info
- Publication number
- FR14C0041I1 FR14C0041I1 FR14C0041C FR14C0041I1 FR 14C0041 I1 FR14C0041 I1 FR 14C0041I1 FR 14C0041 C FR14C0041 C FR 14C0041C FR 14C0041 I1 FR14C0041 I1 FR 14C0041I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005131161 | 2005-04-28 | ||
JP2005312076 | 2005-10-27 | ||
PCT/US2006/016604 WO2006116764A1 (fr) | 2005-04-28 | 2006-04-28 | Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih |
Publications (2)
Publication Number | Publication Date |
---|---|
FR14C0041I1 true FR14C0041I1 (fr) | 2014-06-27 |
FR14C0041I2 FR14C0041I2 (fr) | 2015-11-13 |
Family
ID=37215098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR14C0041C Active FR14C0041I2 (fr) | 2005-04-28 | 2014-05-19 | Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih |
Country Status (29)
Country | Link |
---|---|
US (21) | US8129385B2 (fr) |
EP (9) | EP1874117B8 (fr) |
JP (2) | JP4295353B2 (fr) |
KR (4) | KR101848819B1 (fr) |
AU (1) | AU2006239177B8 (fr) |
BR (1) | BRPI0610030B8 (fr) |
CA (1) | CA2606282C (fr) |
CY (6) | CY1115151T1 (fr) |
DK (6) | DK2465580T3 (fr) |
EA (1) | EA014162B1 (fr) |
ES (7) | ES2667868T5 (fr) |
FI (1) | FIC20210017I1 (fr) |
FR (1) | FR14C0041I2 (fr) |
HK (4) | HK1107227A1 (fr) |
HU (6) | HUE056603T2 (fr) |
IL (4) | IL186555A (fr) |
LT (4) | LT3372281T (fr) |
LU (2) | LU92446I2 (fr) |
MA (1) | MA29460B1 (fr) |
MX (2) | MX302718B (fr) |
NL (2) | NL300676I2 (fr) |
NO (5) | NO339525B1 (fr) |
NZ (1) | NZ562339A (fr) |
PL (5) | PL2465580T3 (fr) |
PT (5) | PT3284520T (fr) |
SI (6) | SI3045206T1 (fr) |
TW (1) | TWI378931B (fr) |
VN (1) | VN34404A1 (fr) |
WO (1) | WO2006116764A1 (fr) |
Families Citing this family (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2287167A1 (fr) | 2003-12-24 | 2011-02-23 | Biota Scientific Management Pty. Ltd. | Agents polycycliques pour le traitement des infections de virus respiratoire syncytial |
US7273859B2 (en) * | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
ES2667868T5 (es) | 2005-04-28 | 2023-06-01 | Viiv Healthcare Co | Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora de la integrasa del VIH |
EP1881825B1 (fr) | 2005-05-10 | 2013-07-24 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'intégrase du vih |
CA2622639C (fr) | 2005-10-04 | 2012-01-03 | Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. | Inhibiteurs de l'integrase du vih |
ES2569357T3 (es) * | 2005-10-27 | 2016-05-10 | Shionogi & Co., Ltd. | Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora sobre integrasa de HIV |
TWI423972B (zh) | 2006-09-28 | 2014-01-21 | Biota Scient Management | 治療呼吸系融合細胞病毒感染之多環劑 |
JP5269086B2 (ja) | 2007-11-15 | 2013-08-21 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルスの複製阻害薬 |
JP5269085B2 (ja) * | 2007-11-15 | 2013-08-21 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルス複製のインヒビター |
CN101918365B (zh) | 2007-11-16 | 2013-10-09 | 吉联亚科学股份有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
EP2320909B8 (fr) | 2008-07-25 | 2016-03-30 | VIIV Healthcare Company | Composés chimiques |
WO2010011815A1 (fr) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Composés chimiques |
WO2010011818A1 (fr) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Composés chimiques |
EP2330902B1 (fr) * | 2008-07-25 | 2012-11-14 | GlaxoSmithKline LLC | Composés chimiques |
PT2320908E (pt) * | 2008-07-25 | 2014-03-06 | Shionogi & Co | Pró-fármacos de dolutegravir |
AU2014277831C1 (en) * | 2008-12-11 | 2022-10-06 | Shionogi & Co. Ltd. | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
ES2763540T3 (es) * | 2008-12-11 | 2020-05-29 | Viiv Healthcare Co | Intermedios para inhibidores de la integrasa del VIH de carbamoilpiridona |
BRPI0923217A2 (pt) * | 2008-12-11 | 2017-05-23 | Glaxosmithkline Llc | processos para a preparação de um composto de piridona, e para a preparação de uma forma cristalina, composto, sal ou um hidrato deste, forma cristalina de um sal de sódio ou um hidrato deste, e, composição farmacêutica. |
EP2370419B1 (fr) * | 2008-12-11 | 2017-09-27 | Shionogi&Co., Ltd. | Procédés et intermédiaires associés à l éther de maltol |
TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
TWI520959B (zh) | 2009-06-15 | 2016-02-11 | 鹽野義製藥股份有限公司 | 經取代的多環胺甲醯吡啶酮衍生物及其用途 |
WO2011011483A1 (fr) * | 2009-07-22 | 2011-01-27 | Glaxosmithkline Llc | Composés chimiques |
EP2488521B1 (fr) | 2009-10-13 | 2013-12-18 | Elanco Animal Health Ireland Limited | Inhibiteurs de l'intégrase macrocyclique |
EA202190473A3 (ru) * | 2010-01-27 | 2021-12-31 | Вайв Хелткер Компани | Противовирусная терапия |
AU2014202404C1 (en) * | 2010-01-27 | 2022-06-23 | Viiv Healthcare Company | Antiviral therapy |
AU2014202405B2 (en) * | 2010-01-27 | 2016-02-25 | Viiv Healthcare Company | Antiviral therapy |
TWI508968B (zh) * | 2010-02-08 | 2015-11-21 | Biota Scient Management | 用於治療呼吸道融合性病毒感染的化合物 |
NZ601847A (en) * | 2010-02-26 | 2014-03-28 | Japan Tobacco Inc | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
TWI582097B (zh) * | 2010-03-23 | 2017-05-11 | Viiv醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
US8716293B2 (en) | 2010-04-02 | 2014-05-06 | Janssen R&D Ireland | Macrocyclic integrase inhibitors |
JP5766690B2 (ja) * | 2010-04-12 | 2015-08-19 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有するピリドン誘導体 |
US9073941B2 (en) | 2010-06-28 | 2015-07-07 | Academia Sinica | Compounds and methods for treating tuberculosis infection |
ES2710609T3 (es) | 2010-08-05 | 2019-04-26 | Shionogi & Co | Procedimiento de preparación de un compuesto que tiene actividad inhibidora de la integrasa del HIV |
TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Viiv醫療保健公司 | 醫藥組合物 |
AU2011307087B2 (en) * | 2010-09-24 | 2016-11-10 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoyl pyridone derivative prodrug |
US8796303B2 (en) | 2010-11-26 | 2014-08-05 | Biota Scientific Management Pty Ltd. | Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections |
WO2012151361A1 (fr) | 2011-05-03 | 2012-11-08 | Concert Pharmaceuticals Inc. | Dérivés de carbamoylpyridone |
PL2742051T3 (pl) | 2011-09-14 | 2017-06-30 | Mapi Pharma Limited | Amorficzna postać soli sodowej dolutegrawiru |
BR112014008896A2 (pt) * | 2011-10-12 | 2017-04-18 | Shionogi & Co | derivado de piridona policíclico tendo atividade inibidora de integrase |
HUE035069T2 (en) | 2011-12-28 | 2018-05-02 | Global Blood Therapeutics Inc | Substituted benzaldehyde compounds and their use to increase tissue oxygenation |
ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
WO2014099586A1 (fr) | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | Dérivés 4-pyridinonetriazines en tant qu'inhibiteurs de l'intégrase du vih |
SI2822954T1 (sl) * | 2012-12-21 | 2016-07-29 | Gilead Sciences, Inc. | Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba |
SG11201504982PA (en) * | 2012-12-27 | 2015-07-30 | Japan Tobacco Inc | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR |
CA2897137A1 (fr) | 2013-02-18 | 2014-08-21 | Ratiopharm Gmbh | Forme galenique pharmaceutique solide de dolutegravir |
EP2767272A1 (fr) | 2013-02-18 | 2014-08-20 | Ratiopharm GmbH | Forme posologique pharmaceutique solide de dolutegravir |
WO2014128545A2 (fr) | 2013-02-19 | 2014-08-28 | Aurobindo Pharma Limited | Procédé amélioré pour la préparation du dolutégravir |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CN112500338A (zh) | 2013-03-15 | 2021-03-16 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
AP2015008718A0 (en) | 2013-03-15 | 2015-09-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
WO2014145040A1 (fr) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Composés aldéhydes substitués et leurs procédés d'utilisation pour accroître l'oxygénation tissulaire |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
PE20151900A1 (es) | 2013-03-15 | 2016-01-20 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EP2986291B1 (fr) | 2013-04-16 | 2020-05-27 | Merck Sharp & Dohme Corp. | Composés dérivés de 4-pyridone et leurs utilisations en tant qu'inhibiteurs de la vih intégrase |
US9951079B2 (en) * | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
WO2015001572A2 (fr) * | 2013-07-04 | 2015-01-08 | Hetero Research Foundation | Procédé pour la préparation d'intermédiaire de dolutégravir |
NO2865735T3 (fr) | 2013-07-12 | 2018-07-21 | ||
EP3252058B1 (fr) * | 2013-07-12 | 2021-01-20 | Gilead Sciences, Inc. | Composés polycycliques-carbamoylpyridone et leur utilisation pour le traitement des infections par vih |
WO2015009927A1 (fr) | 2013-07-17 | 2015-01-22 | Ratiopharm Gmbh | Sels de dolutégravir |
WO2015019310A1 (fr) | 2013-08-07 | 2015-02-12 | Mylan Laboratories Ltd | Procédé de préparation de dolutégravir et ses intermédiaires |
WO2015039348A1 (fr) * | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tétracycliques utiles comme inhibiteurs de l'intégrase du vih |
EP3049081B1 (fr) * | 2013-09-27 | 2019-11-27 | Merck Sharp & Dohme Corp. | Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih |
EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
WO2015092752A1 (fr) | 2013-12-20 | 2015-06-25 | Mylan Laboratories Ltd. | Nouvelle forme cristalline de dolutegravir sodium |
WO2015089847A1 (fr) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Composés à hétérocycles spirocycliques utiles en tant qu'inhibiteurs d'intégrase du vih |
WO2015108945A2 (fr) | 2014-01-14 | 2015-07-23 | Board Of Regents Of The University Of Nebraska | Compositions et méthodes pour l'administration d'agents thérapeutiques |
WO2015110897A2 (fr) * | 2014-01-21 | 2015-07-30 | Laurus Labs Private Limited | Nouveau procédé de préparation de dolutégravir et de ses sels pharmaceutiquement acceptables |
CN114181194A (zh) | 2014-02-07 | 2022-03-15 | 全球血液疗法股份有限公司 | 一种化合物的结晶多晶型物 |
WO2015138933A1 (fr) | 2014-03-13 | 2015-09-17 | Assia Chemical Industries Ltd. | Formes à l'état solide de dolutegravir sodium |
CN106866701B (zh) * | 2014-03-19 | 2019-03-19 | 杭州普晒医药科技有限公司 | 德罗格韦钠盐的晶型及其制备方法 |
WO2015140569A1 (fr) | 2014-03-20 | 2015-09-24 | Cipla Limited | Composition pharmaceutique |
ZA201503540B (en) * | 2014-05-20 | 2016-10-26 | Cipla Ltd | Process for preparing polycyclic carbamoyl pyridone derivatives |
TWI744723B (zh) * | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
NO2717902T3 (fr) * | 2014-06-20 | 2018-06-23 | ||
TW201613936A (en) * | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
JPWO2016027879A1 (ja) * | 2014-08-22 | 2017-06-01 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
WO2016057866A1 (fr) | 2014-10-09 | 2016-04-14 | Board Of Regents Of The University Of Nebraska | Compositions et méthodes d'administration d'agents thérapeutiques |
WO2016092527A1 (fr) * | 2014-12-12 | 2016-06-16 | Sun Pharmaceutical Industries Limited | Procédé de préparation de dolutégravir |
TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
EP3045461A1 (fr) | 2015-01-16 | 2016-07-20 | LEK Pharmaceuticals d.d. | Procédés de préparation de Dolutégravir et de ses analogues |
WO2016125192A2 (fr) | 2015-02-06 | 2016-08-11 | Mylan Laboratories Limited | Procédé de préparation de dolutégravir |
CZ201599A3 (cs) | 2015-02-13 | 2016-08-24 | Zentiva, K.S. | Pevné formy solí dolutegraviru a způsob jejich přípravy |
WO2016154527A1 (fr) * | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Dérivés de quinolizine substitués par un phosphate utiles en tant qu'inhibiteurs de l'intégrase du vih |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
CA2980362C (fr) * | 2015-04-02 | 2020-02-25 | Gilead Sciences, Inc. | Composes carbamoylpyridones polycycliques et leur utilisation pharmaceutique |
SI3428170T1 (sl) * | 2015-04-28 | 2021-03-31 | Shionogi & Co., Ltd | Policiklični piridonski derivat proti gripi in njegovo predzdravilo |
WO2016187788A1 (fr) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tricycliques fusionnés utiles pour traiter l'infection au vih |
CZ2015537A3 (cs) | 2015-08-04 | 2017-02-15 | Zentiva, K.S. | Pevné formy amorfního dolutegraviru |
US10597404B2 (en) | 2015-08-19 | 2020-03-24 | Laurus Labs Ltd. | Polymorphs of dolutegravir and salts thereof |
NZ741957A (en) | 2015-11-09 | 2019-04-26 | Gilead Sciences Inc | Therapeutic compositions for treatment of human immunodeficiency virus |
EP3377066B1 (fr) | 2015-11-17 | 2021-04-07 | Merck Sharp & Dohme Corp. | Dérivés de pyridotriazine amido-substitués utiles en tant qu'inhibiteurs de l'intégrase du vih |
SG10201912511WA (en) | 2015-12-04 | 2020-02-27 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
US10544155B2 (en) | 2015-12-15 | 2020-01-28 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors |
US10696636B2 (en) | 2015-12-21 | 2020-06-30 | Lupin Limited | Process for the preparation of HIV integrase inhibitors |
AR108435A1 (es) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído |
WO2017208105A1 (fr) | 2016-05-30 | 2017-12-07 | Lupin Limited | Nouvelle forme cristalline de dolutégravir sodique |
WO2017223280A2 (fr) * | 2016-06-23 | 2017-12-28 | Viiv Healthcare Company | Compositions et méthodes de libération d'agents thérapeutiques |
US20190175511A1 (en) | 2016-08-08 | 2019-06-13 | Hetero Labs Limited | A Multi-Class Anti-Retroviral Composition |
US11045423B2 (en) | 2016-08-08 | 2021-06-29 | Hetero Labs Limited | Anti-retroviral compositions |
EP3496724B8 (fr) * | 2016-08-12 | 2021-11-17 | Madera Therapeutics, LLC | Régulateurs de protéine kinases |
WO2018042332A1 (fr) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinaisons, utilisations et traitements correspondants |
WO2018057408A1 (fr) * | 2016-09-21 | 2018-03-29 | Merck Sharp & Dohme Corp. | Système d'administration de médicaments pour l'administration d'inhibiteurs de l'intégrase |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
JP2020500866A (ja) | 2016-12-02 | 2020-01-16 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Hivインテグラーゼ阻害剤として有用な三環式複素環化合物 |
JOP20190130A1 (ar) * | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
WO2018109786A1 (fr) | 2016-12-16 | 2018-06-21 | Cipla Limited | Nouveaux polymorphes et sels de dérivés de carbamoyle pyridone polycycliques |
US10786488B2 (en) | 2017-01-26 | 2020-09-29 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as HIV integrase inhibitors |
EP3363802B1 (fr) | 2017-02-16 | 2019-11-20 | Sandoz AG | Forme cristalline du sel de sodium de cabotegravir |
AU2018221379B2 (en) * | 2017-02-16 | 2021-11-04 | ViiV Healthcare UK (No.3) Limited | Crystalline forms of cabotegravir sodium |
EP3655106A4 (fr) * | 2017-07-18 | 2021-04-21 | VIIV Healthcare Company | Polythérapie |
WO2019016732A1 (fr) | 2017-07-21 | 2019-01-24 | Viiv Healthcare Company | Régimes pour le traitement des infections du vih et du sida |
EP3661940A1 (fr) | 2017-09-07 | 2020-06-10 | Cipla Limited | Nouveaux polymorphes du dolutégravir sodique |
SG11202002789XA (en) | 2017-10-06 | 2020-04-29 | Shionogi & Co | Stereoselective process for preparing substituted polycyclic pyridone derivatives |
WO2019140365A1 (fr) | 2018-01-12 | 2019-07-18 | Board Of Regents Of The University Of Nebraska | Promédicaments antiviraux et formulations de ceux-ci |
WO2019159199A1 (fr) | 2018-02-16 | 2019-08-22 | Cipla Limited | Procédé à flux continu pour la préparation de dérivés de carbamoylpyridone polycycliques à ingrédients pharmaceutiquement actifs et intermédiaires de ceux-ci |
WO2019199756A1 (fr) | 2018-04-09 | 2019-10-17 | Board Of Regents Of The University Of Nebraska | Promédicaments antiviraux et formulations de ceux-ci |
CN110526930B (zh) | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
TW202323254A (zh) * | 2018-05-31 | 2023-06-16 | 日商鹽野義製藥股份有限公司 | 多環性吡啶并三𠯤衍生物 |
CN117327072A (zh) | 2018-05-31 | 2024-01-02 | 盐野义制药株式会社 | 多环氨基甲酰基吡啶酮衍生物 |
WO2019230857A1 (fr) | 2018-05-31 | 2019-12-05 | 塩野義製薬株式会社 | Dérivé de pyridone polycyclique |
US11634431B2 (en) | 2018-07-12 | 2023-04-25 | Laurus Labs Limited | Process for purification of protected polycyclic carbamoylpyridone derivatives |
EP3860975B1 (fr) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulateurs de l'hémoglobine pour le traitement de la drépanocytose |
WO2020086555A1 (fr) | 2018-10-22 | 2020-04-30 | Board Of Regents Of The University Of Nebraska | Promédicaments antiviraux et nanoformulations de ceux-ci |
US11084832B2 (en) | 2019-03-22 | 2021-08-10 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
RU2717101C1 (ru) * | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
US11248005B2 (en) | 2019-07-08 | 2022-02-15 | Lupin Limited | Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor |
US20230059640A1 (en) | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
UY38982A (es) | 2019-12-09 | 2021-06-30 | Viiv Healthcare Co | Composiciones farmacéuticas |
CN115151545A (zh) | 2020-02-24 | 2022-10-04 | 吉利德科学公司 | 用于治疗hiv感染的四环化合物 |
WO2021209563A1 (fr) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Composés destinés à être utilisés dans le traitement d'infections virales par un coronavirus associé au syndrome respiratoire |
JP2023539344A (ja) | 2020-09-01 | 2023-09-13 | ヴィーブ、ヘルスケア、カンパニー | カボテグラビルおよびレボノルゲストレルの組合せ |
WO2022079739A1 (fr) | 2020-10-14 | 2022-04-21 | Cipla Limited | Compositions à dose fixe de cabotégravir et de rilpivirine |
EP4255472A2 (fr) | 2020-12-07 | 2023-10-11 | VIIV Healthcare Company | Polythérapie |
LT4196479T (lt) | 2021-01-19 | 2023-12-11 | Gilead Sciences, Inc. | Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai |
CN117715908A (zh) | 2021-06-03 | 2024-03-15 | 江苏恒瑞医药股份有限公司 | 具有整合酶抑制活性的吡啶酮化合物及其药用用途 |
CN114230579A (zh) * | 2021-11-12 | 2022-03-25 | 南京艾迪医药科技有限公司 | 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物 |
WO2023102374A1 (fr) | 2021-12-03 | 2023-06-08 | Viiv Healthcase Company | Procédé de synthèse de (r)-3-aminobutan-1-ol |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3959316A (en) * | 1972-03-13 | 1976-05-25 | Snam Progetti S.P.A. | Procedure for propylene oxide synthesis |
JPH0296506A (ja) | 1988-09-30 | 1990-04-09 | Daicel Chem Ind Ltd | 除草剤組成物 |
JP2533796B2 (ja) | 1988-10-18 | 1996-09-11 | ダイセル化学工業株式会社 | 5−アルコキシピリジン−3−カルボキサミド誘導体とその製造方法及び植物成長抑制剤 |
JP2551472B2 (ja) | 1988-10-18 | 1996-11-06 | ダイセル化学工業株式会社 | 5−アルコキシ−γ−ピロン−3−カルボキサミド誘導体とその製造方法及び植物成長抑制剤 |
AU755707B2 (en) | 1997-12-22 | 2002-12-19 | Pharmacia & Upjohn Company | 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents |
US20040039060A1 (en) † | 2000-06-14 | 2004-02-26 | Ryuichi Kiyama | Inhibitor for enzyme having two divalent metal ions as active centers |
US6580562B2 (en) | 2000-07-24 | 2003-06-17 | Yazaki Corporation | On-vehicle display unit |
US6384263B1 (en) | 2000-08-04 | 2002-05-07 | E. I. Du Pont De Nemours And Company | Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane |
WO2002030426A1 (fr) | 2000-10-12 | 2002-04-18 | Merck & Co., Inc. | Azanaphthalenylcarboxamides et polyazanaphthalenylcarboxamides utiles en tant qu'inhibiteurs de la vih integrase |
JP2003032772A (ja) | 2001-07-12 | 2003-01-31 | Foster Electric Co Ltd | 耳掛け式イヤホン |
CN101513402B (zh) | 2001-08-10 | 2012-03-21 | 盐野义制药株式会社 | 抗病毒药 |
DE60218511T2 (de) | 2001-10-26 | 2007-10-25 | Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
ES2258668T3 (es) | 2001-10-26 | 2006-09-01 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Hidroxipirimidina carboxamidas n-sustituidas inhibidoras de hiv integrasa. |
CA2472372C (fr) | 2002-01-17 | 2010-08-17 | Melissa Egbertson | Carboxamides hydroxynaphthyridinone utiles comme inhibiteurs de l'integrase du vih |
WO2004004657A2 (fr) | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Inhibiteurs de l'integrase du vih |
EP1541558B1 (fr) | 2002-08-13 | 2008-08-13 | Shionogi & Co., Ltd. | Composes heterocycliques a activite inhibitrice de l'integrase du vih |
CA2498111A1 (fr) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Composes de dihydroxypyridopyrazine-1,6-diones utiles en tant qu'inhibiteurs de l'integrase du vih |
RU2329265C2 (ru) | 2002-12-27 | 2008-07-20 | Институто Ди Ричерке Ди Биолоджиа Молеколаре П.Анджелетти Спа | ТЕТРАГИДРО-4Н-ПИРИДО[1,2-а]ПИРИМИДИНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ВИЧ-ИНТЕГРАЗЫ |
US6960680B2 (en) | 2003-01-08 | 2005-11-01 | Rhodia Chirex, Inc. | Manufacture of water-soluble β-hydroxynitriles |
JP2004244320A (ja) | 2003-02-10 | 2004-09-02 | Shionogi & Co Ltd | 含窒素複素環抗ウイルス剤 |
WO2004101512A2 (fr) | 2003-05-13 | 2004-11-25 | Smithkline Beecham Corporation | Inihbiteurs de l'integrase de la naphtyridine |
AU2003273190A1 (en) * | 2003-08-12 | 2005-02-25 | Rachel Beijer | Scheduled message service |
TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
JP4530642B2 (ja) | 2003-10-31 | 2010-08-25 | オリンパス株式会社 | 内視鏡装置 |
RU2006128848A (ru) | 2004-02-11 | 2008-03-20 | СмитКлайн Бичем Корпорейшн (US) | Ингибиторы вич-интегразы |
US7820680B2 (en) | 2004-03-09 | 2010-10-26 | Merck & Co., Inc. | HIV integrase inhibitors |
JP2007528379A (ja) | 2004-03-09 | 2007-10-11 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Hivインテグラーゼ阻害薬 |
WO2005110415A1 (fr) | 2004-05-07 | 2005-11-24 | Merck & Co., Inc. | Inhibiteurs d’intégrase du vih |
CA2634499A1 (fr) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones et procedes d'inhibition de l'integrase du vih |
EP1852434B1 (fr) | 2005-02-21 | 2011-07-13 | Shionogi Co., Ltd. | Dérivé de carbamoylpyridone bicyclique ayant une activité d'inhibition de la vih intégrase |
CA2600832C (fr) | 2005-03-31 | 2011-12-13 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Inhibiteurs de l'integrase du vih |
ES2667868T5 (es) * | 2005-04-28 | 2023-06-01 | Viiv Healthcare Co | Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora de la integrasa del VIH |
JP2005312076A (ja) | 2005-05-26 | 2005-11-04 | Olympus Corp | 電子撮像装置 |
JP2009503081A (ja) | 2005-08-04 | 2009-01-29 | スミスクライン ビーチャム コーポレーション | Hivインテグラーゼ阻害薬 |
ES2569357T3 (es) | 2005-10-27 | 2016-05-10 | Shionogi & Co., Ltd. | Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora sobre integrasa de HIV |
-
2006
- 2006-04-28 ES ES16154531T patent/ES2667868T5/es active Active
- 2006-04-28 HU HUE18166621A patent/HUE056603T2/hu unknown
- 2006-04-28 EP EP06758843.4A patent/EP1874117B8/fr active Active
- 2006-04-28 PT PT17195280T patent/PT3284520T/pt unknown
- 2006-04-28 EP EP12159082.2A patent/EP2465580B1/fr active Active
- 2006-04-28 ES ES17195280T patent/ES2743531T3/es active Active
- 2006-04-28 ES ES17156762T patent/ES2906792T3/es active Active
- 2006-04-28 TW TW095115285A patent/TWI378931B/zh active
- 2006-04-28 MX MX2007013351A patent/MX302718B/es active IP Right Grant
- 2006-04-28 US US11/919,386 patent/US8129385B2/en active Active
- 2006-04-28 JP JP2008509227A patent/JP4295353B2/ja active Active
- 2006-04-28 ES ES12159082.2T patent/ES2446324T3/es active Active
- 2006-04-28 EP EP18166621.5A patent/EP3372281B1/fr active Active
- 2006-04-28 SI SI200632268T patent/SI3045206T1/en unknown
- 2006-04-28 ES ES06758843.4T patent/ES2437268T3/es active Active
- 2006-04-28 SI SI200632344T patent/SI3284520T1/sl unknown
- 2006-04-28 EP EP16154531.4A patent/EP3045206B2/fr active Active
- 2006-04-28 DK DK12159082.2T patent/DK2465580T3/en active
- 2006-04-28 HU HUE17195280 patent/HUE044978T2/hu unknown
- 2006-04-28 EP EP17195280.7A patent/EP3284520B1/fr active Active
- 2006-04-28 AU AU2006239177A patent/AU2006239177B8/en active Active
- 2006-04-28 DK DK16154531.4T patent/DK3045206T3/en active
- 2006-04-28 SI SI200632418T patent/SI3187225T1/sl unknown
- 2006-04-28 SI SI200632410T patent/SI3372281T1/sl unknown
- 2006-04-28 DK DK17195280.7T patent/DK3284520T3/da active
- 2006-04-28 PT PT161545314T patent/PT3045206T/pt unknown
- 2006-04-28 LT LTEP18166621.5T patent/LT3372281T/lt unknown
- 2006-04-28 PL PL12159082T patent/PL2465580T3/pl unknown
- 2006-04-28 EP EP17156762.1A patent/EP3187225B1/fr active Active
- 2006-04-28 PT PT121590822T patent/PT2465580E/pt unknown
- 2006-04-28 DK DK06758843.4T patent/DK1874117T3/da active
- 2006-04-28 BR BRPI0610030A patent/BRPI0610030B8/pt active IP Right Grant
- 2006-04-28 CA CA2606282A patent/CA2606282C/fr active Active
- 2006-04-28 ES ES12159079.8T patent/ES2567197T3/es active Active
- 2006-04-28 HU HUE16154531A patent/HUE037795T2/hu unknown
- 2006-04-28 PT PT67588434T patent/PT1874117E/pt unknown
- 2006-04-28 EA EA200702080A patent/EA014162B1/ru active Protection Beyond IP Right Term
- 2006-04-28 DK DK18166621.5T patent/DK3372281T3/da active
- 2006-04-28 ES ES18166621T patent/ES2892304T3/es active Active
- 2006-04-28 PT PT181666215T patent/PT3372281T/pt unknown
- 2006-04-28 SI SI200631703T patent/SI1874117T1/sl unknown
- 2006-04-28 LT LTEP17195280.7T patent/LT3284520T/lt unknown
- 2006-04-28 LT LTEP16154531.4T patent/LT3045206T/lt unknown
- 2006-04-28 PL PL18166621T patent/PL3372281T3/pl unknown
- 2006-04-28 WO PCT/US2006/016604 patent/WO2006116764A1/fr active Application Filing
- 2006-04-28 EP EP17195276.5A patent/EP3284519A1/fr active Pending
- 2006-04-28 PL PL16154531T patent/PL3045206T3/pl unknown
- 2006-04-28 PL PL06758843T patent/PL1874117T3/pl unknown
- 2006-04-28 NZ NZ562339A patent/NZ562339A/en unknown
- 2006-04-28 VN VN201300151A patent/VN34404A1/vi unknown
- 2006-04-28 PL PL17195280T patent/PL3284520T3/pl unknown
- 2006-04-28 KR KR1020157036007A patent/KR101848819B1/ko active IP Right Review Request
- 2006-04-28 DK DK17156762.1T patent/DK3187225T3/da active
- 2006-04-28 EP EP17156763.9A patent/EP3187226A1/fr not_active Withdrawn
- 2006-04-28 KR KR1020077027734A patent/KR101363875B1/ko active IP Right Review Request
- 2006-04-28 SI SI200631747T patent/SI2465580T1/sl unknown
- 2006-04-28 EP EP12159079.8A patent/EP2527007B1/fr active Active
- 2006-04-28 KR KR1020147017235A patent/KR101580310B1/ko active IP Right Grant
- 2006-04-28 KR KR1020137028203A patent/KR101504998B1/ko active IP Right Grant
-
2007
- 2007-10-10 IL IL186555A patent/IL186555A/en active IP Right Grant
- 2007-10-10 NO NO20075165A patent/NO339525B1/no active Protection Beyond IP Right Term
- 2007-10-25 MX MX2011010484A patent/MX312216B/es unknown
- 2007-11-20 MA MA30388A patent/MA29460B1/fr unknown
-
2008
- 2008-01-24 HK HK08100942.1A patent/HK1107227A1/xx unknown
- 2008-10-08 JP JP2008261344A patent/JP2009079058A/ja active Pending
-
2011
- 2011-10-23 IL IL215788A patent/IL215788A0/en unknown
-
2012
- 2012-01-18 US US13/352,686 patent/US8410103B2/en active Active
- 2012-12-18 HK HK12113039.2A patent/HK1172282A1/xx unknown
-
2013
- 2013-02-08 US US13/763,174 patent/US8778943B2/en active Active
- 2013-03-14 IL IL225207A patent/IL225207A/en active IP Right Review Request
- 2013-03-14 IL IL225206A patent/IL225206A/en active IP Right Grant
- 2013-11-27 CY CY20131101061T patent/CY1115151T1/el unknown
-
2014
- 2014-03-13 CY CY20141100201T patent/CY1116331T1/el unknown
- 2014-03-14 US US14/211,364 patent/US9051337B2/en active Active
- 2014-05-07 LU LU92446C patent/LU92446I2/fr unknown
- 2014-05-19 FR FR14C0041C patent/FR14C0041I2/fr active Active
- 2014-06-25 CY CY2014024C patent/CY2014024I1/el unknown
- 2014-07-03 NL NL300676C patent/NL300676I2/nl unknown
- 2014-07-09 HU HUS1400039C patent/HUS1400039I1/hu unknown
-
2015
- 2015-04-30 US US14/700,679 patent/US9273065B2/en active Active
-
2016
- 2016-01-20 US US15/001,336 patent/US20160137666A1/en not_active Abandoned
- 2016-03-31 US US15/086,616 patent/US20160207939A1/en not_active Abandoned
- 2016-06-29 US US15/196,245 patent/US20160304535A1/en not_active Abandoned
- 2016-08-18 NO NO20161315A patent/NO340111B1/no active Protection Beyond IP Right Term
- 2016-10-11 US US15/290,094 patent/US20170029438A1/en not_active Abandoned
-
2017
- 2017-02-08 US US15/427,184 patent/US20170145033A1/en not_active Abandoned
- 2017-03-27 NO NO2017010C patent/NO2017010I2/no unknown
- 2017-04-10 US US15/482,896 patent/US20170209454A1/en not_active Abandoned
- 2017-04-27 US US15/498,667 patent/US20170224694A1/en not_active Abandoned
- 2017-04-27 US US15/498,684 patent/US20170224695A1/en not_active Abandoned
- 2017-05-17 US US15/597,343 patent/US20170253616A1/en not_active Abandoned
- 2017-05-18 US US15/598,671 patent/US20170267693A1/en not_active Abandoned
- 2017-05-18 US US15/598,655 patent/US20170260203A1/en not_active Abandoned
- 2017-09-07 US US15/697,847 patent/US20170369509A1/en not_active Abandoned
-
2018
- 2018-06-19 CY CY20181100633T patent/CY1120345T1/el unknown
- 2018-07-16 HK HK18109159.8A patent/HK1249742A1/zh unknown
- 2018-08-16 HK HK18110519.1A patent/HK1251191A1/zh unknown
-
2019
- 2019-01-10 US US16/244,441 patent/US20190152990A1/en not_active Abandoned
- 2019-05-01 US US16/400,373 patent/US10927129B2/en active Active
- 2019-08-20 CY CY20191100891T patent/CY1122052T1/el unknown
-
2020
- 2020-07-09 US US16/924,390 patent/US11267823B2/en active Active
-
2021
- 2021-05-10 NO NO2021018C patent/NO2021018I1/no unknown
- 2021-06-08 NL NL301109C patent/NL301109I1/nl unknown
- 2021-06-10 FI FIC20210017C patent/FIC20210017I1/fi unknown
- 2021-06-14 HU HUS2100023C patent/HUS2100023I1/hu unknown
- 2021-06-14 HU HUS2100022C patent/HUS2100022I1/hu unknown
- 2021-06-15 LU LU00210C patent/LUC00210I2/en unknown
- 2021-06-16 LT LTPA2021512C patent/LTC2465580I2/lt unknown
- 2021-10-06 CY CY20211100866T patent/CY1124601T1/el unknown
-
2022
- 2022-01-27 US US17/586,006 patent/US20220213121A1/en not_active Abandoned
-
2023
- 2023-11-08 NO NO2023042C patent/NO2023042I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTPA2021512I1 (fr) | ||
BE2012C042I2 (fr) | ||
BRPI0601358B8 (pt) | Aplicador de clipe cirúrgico | |
BRPI0601402B8 (pt) | Aplicador de grampos cirúrgicos | |
BR122017004709A2 (fr) | ||
JP2005187480A5 (fr) | ||
BRPI0609157A8 (fr) | ||
BRPI0608519A2 (fr) | ||
BR122020005056A2 (fr) | ||
AP2140A (fr) | ||
JP2005223321A5 (fr) | ||
JP2006049913A5 (fr) | ||
BR122016029989A2 (fr) | ||
JP2007033412A5 (fr) | ||
JP2007072371A5 (fr) | ||
DE602006007711D1 (fr) | ||
BRPI0618215B8 (fr) | ||
JP2006160526A5 (fr) | ||
JP2007010871A5 (fr) | ||
JP2006349148A5 (fr) | ||
BY2237U (fr) | ||
JP2006211555A5 (fr) | ||
CN105122969C (fr) | ||
CN300726222S (zh) | 包装纸(金色高金火腿肠) | |
CN300725991S (zh) | 鞋帮 |